Elicio Therapeutics earnings were -$51.9M for the trailing 12 months ending Dec 31, 2024, with N/A growth year over year. The latest ELTX earnings report on Dec 31, 2024 announced Q4 2024 earnings of -$14.0M, down 25.7% from last quarter. For the last reported fiscal year 2024 ending Dec 31, 2024, ELTX reported annual earnings of -$51.9M, with 47.5% growth.
Elicio Therapeutics Earnings Reports & History FAQ
What were Elicio Therapeutics's earnings last quarter?
On ELTX's earnings call on Invalid Date, Elicio Therapeutics (NASDAQ: ELTX) reported Q4 2024 earnings per share (EPS) of -$1.02, up 385.71% year over year. Total ELTX earnings for the quarter were -$14.00 million. In the same quarter last year, Elicio Therapeutics's earnings per share (EPS) was -$0.21.
Is Elicio Therapeutics profitable or losing money?
As of the last Elicio Therapeutics earnings report, Elicio Therapeutics is currently losing money. Elicio Therapeutics's net profit (also called net income) for the twelve months ending Dec 31, 2024 was -$51.90 million, a 47.46% increase year over year.
What was ELTX's earnings growth in the past year?
As of Elicio Therapeutics's earnings date in Invalid Date, Elicio Therapeutics's earnings has grown year over year. ELTX earnings in the past year totalled -$51.90 million.
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.